The ESE Clinical Practice Guideline Revision for the Management of Aggressive Pituitary Tumours and Pituitary Carcinomas is almost complete. The guideline has been revised by a panel of international experts, led by Professor Gerald Raverot.
As a member of ESE, we would like to request your assistance to finalise the document. Please find the relevant confidential Revised Guideline and Supplementary Materials below.
To provide feedback your, please reply to info@ese-hormones.org no later than 24 January 2025 – Please use the subject “ESE Guideline Aggressive Pituitary Tumour - Member Review Comment” and reference the document, page number and line number to which your comment relates.
As with our previous guidelines, we will be implementing a transparent review process. Therefore, every comment by reviewers (including the response of the guideline authors) will be presented in the Appendix of the document. If you would prefer not to be mentioned by name, please indicate this in the email to us.
Please note that until the time of publication, the documents below are confidential and should not be shared.